The SHURUI SP single-port endsocopic surgical system has CE approval. Supply Surgerii Robotics
Surgerii Robotics Co. this month closed $100 million in Sequence D financing. The Beijing-based firm mentioned it is going to use the funding to market its SHURUI single-port surgical robotic each domestically and internationally, in addition to to speed up the manufacturing of its next-generation merchandise.
Single-port surgical procedure is a minimally invasive method involving endoscope and surgical devices by way of a single incision. Surgerii mentioned its SHURUI robotic makes use of snake-like devices and teleoperation know-how to assists clinicians in attaining exact operations.
Surgerii develops, produces, and commercializes laparoscopic surgical robotic programs and equipment. In September 2025, it obtained CE approval in Europe for SHURUI. The firm claimed that it was the second such approval after Intuitive Surgical obtained a CE mark for its da Vinci SP system in 2024.
Surgerii touts surgical improvements
The SHURUI single-port endoscopic surgical system, or SR-ENS-600, is “the world’s first commercially obtainable single-port surgical robotic with snake-like devices,” claimed Surgerii Robotics. The corporate famous that it has been constructing its mental property (IP) portfolio.
The core know-how of the SHURUI SP robotic is predicated on the “Twin Continuum Mechanism” design developed by Prof. Kai Xu of Shanghai Jiao Tong College. Surgerii mentioned the innovation enabled the event of its versatile devices, which might carry out extremely complicated and exact procedures by way of a single 1.8 cm (0.7 in.) incision.
Throughout its financing spherical, traders systematically reviewed Sugerii’s IP, mapping the worldwide technological and patent panorama. This included an in depth comparative evaluation between SHURUI SP and greater than 3,000 legitimate, granted patents held by main endoscopic surgical robotic corporations throughout Europe and the U.S.
Surgerii mentioned the evaluation discovered that, regardless of the extremely dense patent panorama, its robotic “has achieved disruptive innovation and breakthroughs in key applied sciences.” The corporate asserted that its method is considerably distinguished from current surgical patents, offering a strong technological and authorized basis to function and commercialize SHURUI in worldwide markets.
A mimial incision by way of the navel supplies entry for a steerable robotic. Supply: Surgerii Robotics
SHURUI authorized for grownup, pediatric sufferers
The SR-ENS-600 obtained advertising approval from China’s Nationwide Medical Merchandise Administration (NMPA) in June 2023. Surgerii mentioned SHURUI SP was first single-port endoscopic surgical robotic to achieve such approval in China.
In August 2025, the robotic obtained CE certification, enabling its use throughout urology, gynecology, basic surgical procedure, and thoracic surgical procedure for each grownup and pediatric sufferers. Surgerii claimed it’s the solely CE-certified single-port surgical robotic authorized for pediatric use and the primary Chinese language surgical robotic to be licensed for the use in sufferers of all age group.
To this point, the corporate has established scientific cooperation with over 70 Grade A tertiary hospitals in China, carried out greater than 3,000 surgical procedures, been concerned in practically 50 procedures worldwide, and developed over 80 surgical strategies that fill gaps in scientific observe throughout Asia or China. These procedures vary from pancreaticoduodenectomy for pancreatic most cancers to surgical procedures on pediatric sufferers as younger as 7 days previous.
Surgerii mentioned it has demonstrated that its know-how can scale back surgical trauma whereas masking a good broader affected person inhabitants than multi-port surgical robots. SHURUI doesn’t but have U.S. Meals and Drug Administration approval.
An indication of SHURUI’s versatile and patented devices dealing with an egg. Supply: Surgerii Robotics
Funding to spice up European adoption
Loyal Valley Capital, a personal fairness agency specializing in healthcare and know-how improvements, led Surgerii Robotics’ Sequence spherical.
Different contributors included Shanghai Healthcare Capital, a strategic investor in healthcare phase leaders; V Star Capital and DNV Capital, each specializing in healthcare improvements; and Hefei Industrial Funding, an investor with in depth expertise and industrial sources in exhausting know-how and strategic rising industries.
Surgerii famous that this funding got here as it’s deepening its home market penetration and accelerating worldwide commercialization.
“Leveraging the robust assist from this new spherical financing, the corporate will additional the scientific adoption, develop superior power devices, thereby deepening the therapeutic worth of single-port robots in additional and sophisticated instances, in addition to making a disruptive systematic answer centered on cutting-edge know-how to learn a wider vary of sufferers,” it acknowledged.
In 2025, Surgerii established the European Scientific Excellence Heart in collaboration with IRCAD, a number one establishment for minimally invasive surgical coaching. The corporate added that it has set its strategic give attention to the high-end European market.
